.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,563,138

« Back to Dashboard

Claims for Patent: 5,563,138

Title: Benzoheterocyclic compounds
Abstract:Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is cyclopropyl which may have 1 to 3 substituents of alkyl and halogen; phenyl which may be substituted by 1 to 3 substituents of alkoxy, halogen and OH; alkyl which may be substituted by halogen, alkanoyloxy or OH; alkenyl; or thienyl, R.sup.2 is 5- to 9-membered saturated or unsaturated heterocyclic ring which may be sustituted, R.sup.3 is alkyl, R is H or alkyl, and X is halogen, and pharmaceutically acceptable salts thereof, said compounds having excellent antimicrobial activity and hence being useful as an antimicrobial agent, and a pharmaceutical composition containing said compound as an active ingredient.
Inventor(s): Ueda; Hiraki (Mishima, JP), Miyamoto; Hisashi (Tokushima, JP), Yamashita; Hiroshi (Tokushima, JP), Tone; Hitoshi (Itano, JP)
Assignee: Otsuka Pharmaceutical Company, Limited (Tokyo, JP)
Application Number:07/179,239
Patent Claims: 1. A compound of the formula: ##STR36## wherein R.sup.1 is a cyclopropyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C.sub.1 -C.sub.6 alkyl and a halogen atom; a phenyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C.sub.1 -C.sub.6 alkoxy, a halogen atom and hydroxy; a C.sub.1 -C.sub.6 alkyl which may be substituted by a halogen atom, a C.sub.2 -C.sub.6 alkanoyloxy or hydroxy; a C.sub.2 -C.sub.6 alkenyl; or thienyl

is a member selected from the group consisting of a 1-piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkanoyl group, a phenyl (C.sub.1 -C.sub.6) alkyl group, and a 2-oxo-1,3-dioxolenemethyl group which may be substituted by a phenyl group or a C.sub.1 -C.sub.6 alkyl group; a 1-pyrrolidinyl group which may have 1 to 3 substituents selected from the group consisting of an amino group which can have 1 or 2 substituents selected from a C.sub.1 -C.sub.6 alkyl group and a (C.sub.1 -C.sub.6)alkooxy-carbonyl group, an amino(C.sub.1 -C.sub.6)alkyl group which may have 1 to 2 substituents selected from a C.sub.1 -C.sub.6 alkyl group and a (C.sub.1 -C.sub.6)alkoxy-carbonyl group on the amino moiety, and a C.sub.1 -C.sub.6 alkyl group; a morpholino group which may have 1 to 3 substituents of C.sub.1 -C.sub.6 alkyl groups; a 1-piperidinyl group which may have 1 to 3 substituents selected from the group consisting of a C.sub.1 -C.sub.6 alkyl group, hydroxy, a halogen atom and oxo group; and 1,4-diazobicyclo[4.3.0]nonan-4-yl group,

R.sup.3 is a C.sub.1 -C.sub.6 alkyl;

R is hydrogen atom or a C.sub.1 -C.sub.6 alkyl, and

X is a halogen atom,

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein R.sup.1 is a phenyl which may have 1 to 3 substituents selected from the group consisting of a C.sub.1 -C.sub.6 alkoxy group, a halogen atom and hydroxy group, or a C.sub.1 -C.sub.6 alkyl group which may by substituted by a halogen atom, a C.sub.2 -C.sub.6 alkanoyloxy group or hydroxy group, R is hydrogen atom, and X is fluorine atom, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein R.sup.1 is a C.sub.2 -C.sub.6 alkenyl group or thienyl group, R is hydrogen atom, and X is fluorine atom, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1, wherein R.sup.1 is unsubstituted cyclopropyl, R is hydrogen atom, X is fluorine atom, and R.sup.3 is a C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4, wherein R.sup.2 is a 1-piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkanoyl group, a phenyl(C.sub.1 -C.sub.6)alkyl group, and a 2-oxo-1,3-dioxolenemethyl group which may be substituted by phenyl group or a C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5, wherein R.sup.2 is a group of the formula: ##STR37## wherein R.sup.a is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.b is hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkanoyl group, a phenyl(C.sub.1 -C.sub.6)alkyl group, or a 2-oxo-1,3-dioxolenemethyl group which is substituted by a C.sub.1 -C.sub.6 alkyl group, R.sup.c is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 6, wherein R.sup.a is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.b is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.c is hydrogen atom, and R.sup.3 is methyl group, or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 6, wherein R.sup.a is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.b is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.c is hydrogen atom, and R.sup.3 is ethyl group, or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 4, wherein R.sup.2 is a 1-pyrrolidinyl which may have 1 to 3 substituents selected from the group consisting of an amino which may have 1 or 2 substituents selected from a C.sub.1 -C.sub.6 alkyl group and a (C.sub.1 -C.sub.6)alkoxy-carbonyl group, an amino(C.sub.1 -C.sub.6)alkyl group which may have 1 to 2 substituents selected from a C.sub.1 -C.sub.6 alkyl group and a (C.sub.1 -C.sub.6)alkoxy-carbonyl group on the amino moiety, and a C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 9, wherein R.sup.2 is a group of the formula: ##STR38## wherein R.sup.f is an amino which may have 1 or 2 substituents selected from a C.sub.1 -C.sub.6 alkyl group and a (C.sub.1 -C.sub.6)alkoxy-carbonyl group, or an amino(C.sub.1 -C.sub.6)alkyl group which may have 1 or 2 substituents selected from a C.sub.1 -C.sub.6 alkyl group and a (C.sub.1 -C.sub.6)alkoxy-carbonyl group on the amino moiety, R.sup.g is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and R.sup.3 is methyl or ethyl group, or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 4, wherein R.sup.2 is a morpholino group which may have 1 to 3 substituents of C.sub.1 -C.sub.6 alkyl groups, or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 11, wherein R.sup.2 is a group of the formula: ##STR39## wherein R.sup.d is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.e is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and R.sup.3 is methyl or ethyl group, or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 4, wherein R.sup.2 is a 1-piperidinyl group which may have 1 to 3 substituents selected from a C.sub.1 -C.sub.6 alkyl group, hydroxy, a halogen atom and oxo group, or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 13, wherein R.sup.2 is a group of the formula: ##STR40## wherein R.sup.h is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.i is hydrogen atom, hydroxy, a halogen atom or oxo group, R.sup.j is hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; and R.sup.3 is methyl or ethyl group, or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1, wherein R.sup.1 is unsubstituted cyclopropyl, R is hydrogen atom, X is fluorine atom, R.sup.3 is methyl or ethyl group, and R.sup.2 is 1,4-diazabicyclo[4.3.0]nonan-4-yl group, or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 10, wherein R.sup.3 is methyl group, or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 12, wherein R.sup.3 is methyl group, or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 14, wherein R.sup.3 is methyl group, or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 15, wherein R.sup.3 is methyl group, or a pharmaceutically acceptable salt thereof.

20. 7-(1-Piperazinyl)-1-cyclopropyl-6-fluoro -5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

21. 7-(3-Methyl-1-piperazinyl)-1-cyclopropyl-6-fluoro-5 -methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

22. 7-(4-Methyl-1-piperazinyl)-1-cyclopropyl-6-fluoro -5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

23. An antimicrobial composition which comprises an effective antimicrobial amount of a compound as set forth in claim 1 and a pharmaceutically acceptable carrier or diluent.

24. The composition according to claim 23, wherein the active ingredient is the compound as set forth in claim 20.

25. The composition according to claim 23, wherein the active ingredient is the compound as set forth in claim 21.

26. The composition according to claim 23, wherein the active ingredient is the compound as set forth in claim 22.

27. 7-(3-Amino-1-pyrrolidinyl)-1-cyclop ropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

28. 7-(3-Amino-4-methyl-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-5-meth yl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

29. 7-(3-Aminomethyl-1-pyrrolidinyl)-1-cycloprop yl-6-fluoro-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

30. 7-(3-Methylamino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-5-meth yl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.

31. 7-(3-Amino-1-pyrrolidinyl)-1-(2,4-difluoroph enyl)-6-fluoro-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc